The University of Toledo Health Science Campus Division was awarded a $636,185 Project Grant from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) on February 1, 2025. The grant supports research to determine how osteoblasts induce prostate cancer cell dormancy, how treatments affect prostate cancer cell dissemination and dormancy, how the focal adhesion kinase (FAK) inhibitor PF-271 induces dormancy-mimicking, and how PF-271 inhibits prostate cancer bone metastatic progression and recurrence. The research aims to develop new approaches to keep disseminated prostate cancer cells dormant, preventing metastasis and disease recurrence. The findings may lead to an "operational cure" for prostate cancer patients by harnessing dormancy to inhibit disease progression.
Generated 3/4/25, 4:24 AM